ADAR1 (16R16) Rabbit Monoclonal Antibody

ADAR1 (16R16) Rabbit Monoclonal Antibody

规格:50μL 价格:¥1350
规格:100μL 价格:¥2250
应用(Application):WB,IHC-P,FC,IF-P

种属(Reactivity):Human
偶联物(Conjugate):Unconjugated
基因名(Gene Name):ADAR
SKU: AMRe06603 Category: 兔单克隆抗体 Tags: , , , , , , ,

说明书 复制

产品概述

产品名称(Product Name)

ADAR1 (16R16) Rabbit Monoclonal Antibody

描述(Description)

Recombinant rabbit monoclonal antibody

宿主(Host)

Rabbit

应用(Application)

WB,IHC,FC,IF-P

种属反应性(Reactivity)

Human

 

产品性能

偶联物(Conjugation)

Unconjugated

修饰(Modification)

Unmodified

同种型(Isotype)

IgG

克隆(Clonality)

Monoclonal

形式(Form)

Liquid

存放说明(Storage)

Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.

储存溶液(Buffer)

Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% New type preservative N and 50% glycerol. Store at +4°C short term. Store at -20°C long term. Avoid freeze / thaw cycle.

纯化方式(Purification)

Affinity purification

 

免疫原

基因名(Gene Name)

ADAR

别名(Alternative Names)

ADAR; Adar1; AGS6; DRADA; Dsh; Dsrad; IFI4; P136;

基因ID(Gene ID)

103

蛋白ID(SwissProt ID)

P55265

 

产品应用

稀释比(Dilution Ratio)

WB 1:1000-1:5000,IHC 1:50-1:100,FC 1:10-1:100,IF-P 1:50-1:100

蛋白分子量(Molecular Weight)

136kDa

 

研究背景

Converts multiple adenosines to inosines and creates I/U mismatched base pairs in double-helical RNA substrates without apparent sequence specificity. Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing (PubMed:7972084, PubMed:7565688, PubMed:12618436). This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing sequences involved in nuclease recognition; genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication; and RNA structure- dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site- specific editing). Its cellular RNA substrates include: bladder cancer- associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2) and serotonin (HTR2C) and GABA receptor (GABRA3). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alters their functional activities. Exhibits low-level editing at the GRIA2 Q/R site, but edits efficiently at the R/G site and HOTSPOT1. Its viral RNA substrates include: hepatitis C virus (HCV), vesicular stomatitis virus (VSV), measles virus (MV), hepatitis delta virus (HDV), and human immunodeficiency virus type 1 (HIV-1). Exhibits either a proviral (HDV, MV, VSV and HIV-1) or an antiviral effect (HCV) and this can be editing-dependent (HDV and HCV), editing-independent (VSV and MV) or both (HIV-1). Impairs HCV replication via RNA editing at multiple sites. Enhances the replication of MV, VSV and HIV-1 through an editing-independent mechanism via suppression of EIF2AK2/PKR activation and function. Stimulates both the release and infectivity of HIV-1 viral particles by an editing-dependent mechanism where it associates with viral RNAs and edits adenosines in the 5'UTR and the Rev and Tat coding sequence. Can enhance viral replication of HDV via A-to-I editing at a site designated as amber/W, thereby changing an UAG amber stop codon to an UIG tryptophan (W) codon that permits synthesis of the large delta antigen (L-HDAg) which has a key role in the assembly of viral particles. However, high levels of ADAR1 inhibit HDV replication.

 

研究领域

Microbiology


  • 027-87002838

  • order@enkilife.cn

  • 微信客服
  • 企业微信
  • 在线留言
    关闭